Lymphoma classification--the gap between biology and clinical management is closing

Hiddemann, Wolfgang; Longo, Daniela; Coiffier, Bertrand; Fisher, R I; Cabanillas, F; Cavalli, F.; Lm, Nadler; Vita, VT De; Lister, T. A.; Armitage, JO

doi:10.1182/blood.v88.11.4085.4085

Cited by 65 publications

(28 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering that the most profound depression of NK-cell activity was found in patients with high-grade malignancy, commonly constituted by the undifferentiated immunoblastic type of lymphomas, with malignant alteration arising in the lymphoid progenitor cell or renewing peripheral stem cell, this suggests the possibility of a concomitant presence of impairments in other cell types, including NK cells (Caldera et al, 1992;Gaidano, 1997). Also, contrary to previous reports that gave no distinction pertaining to histology (Caldera et al, 1992) or were based on former classifications (Mehta et al, 1989), the connection observed in this study of unfavourable histology with NK-cell depression was an outcome of classification and analysis of non-Hodgkin's lymphoma patients in terms of the recommended International Working Formulation which has proved to be of high prognostic significance and clinical applicability (Rosemberg, 1994;Hiddemann et al, 1996) and is also of more practical use than the REAL classification (Harris et al, 1994).…”

Section: Discussioncontrasting

confidence: 99%

The difference in NK‐cell activity between patients with non‐Hodgkin's lymphomas and Hodgkin's disease

et al. 1999

View full text Add to dashboard Cite

Summary. Natural killer (NK) cells play an important role in immune surveillance against malignant diseases. Considering the lymphoid origin of malignant lymphomas, as well as scarce data concerning NK-cell function in these neoplasms, we evaluated NK-cell activity in 49 patients with nonHodgkin's lymphomas (NHL) and 47 patients with Hodgkin's disease (HD), prior to therapy. Using the recommended International Working Formulation and the Ann Arbor staging system for classification of lymphomas we found, by the LDH release cytotoxicity assay, that decreased NK-cell activity (P < 0·05) in NHL patients was essentially related to unfavourable histology (13 indolent lymphomas, 25 intermediate and 11 very aggressive lymphomas were included), but that within these categories clinical stage of the disease also contributed to the degree of NK-cell dysfunction. In contrast, in HD, NK-cell activity was persistently decreased (P < 0·05), compared to controls, irrespective of histological type and clinical stage. It is of interest also that the most profound NK-cell dysfunction that is present and persistent from the onset of HD, and which appears in very aggressive NHL was associated with the phenomenon of increased spontaneous lactate acid dehydrogenase (LDH) release activity from the separated PBMC of these patients. The difference in the level of NK-cell impairment between patients with various histological grades of malignancy in NHL and HD suggests different initial participation of innate immune reactions in these diseases.

show abstract

Section: Discussioncontrasting

confidence: 99%

The difference in NK‐cell activity between patients with non‐Hodgkin's lymphomas and Hodgkin's disease

et al. 1999

View full text Add to dashboard Cite

show abstract

“…In the past 25 years, the prognosis of patients with malignant lymphoma has improved markedly. Depending on stage, approximately 75-90% of patients with Hodgkin disease (HD) 11 and 40 -50% of patients with high grade/intermediate grade non-Hodgkin lymphoma (NHL) 12 have potentially curable disease. 13,14 Treatment-induced diseases, such as the increased incidence of secondary neoplasms or organ toxicities, have affected the overall survival rate.…”

mentioning

confidence: 99%

2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma

Buchmann

Reinhardt

Elsner

et al. 2001

Cancer

View full text Add to dashboard Cite

show abstract

“…Lymphomas with diffusely growing large blastic cells displaying prominent nucleoli and basophilic cytoplasm and B-cell immunophenotype are labelled diffuse large B-cell lymphomas. In a clinical evaluation of DLBCLs and FCLs according to the REAL classification, DLBCLs and FCLs grade III are classified as aggressive (intermediate risk) lymphomas and FCLs grade I and II as indolent (low risk) lymphomas (Hiddemann et al, 1996).…”

mentioning

confidence: 99%

Gain of chromosome 7 marks the progression from indolent to aggressive follicle centre lymphoma and is a common finding in patients with diffuse large B‐cell lymphoma: a study by FISH

et al. 1998

View full text Add to dashboard Cite

Summary. Gain of chromosome 7 represents one of the most frequent cytogenetic findings in B-cell lymphomas with a follicular growth pattern. We used fluorescence in situ hybridization (FISH) and a probe specifying chromosome 7 on lymph node imprints and/or bone marrow (BM) and peripheral blood (PB) smears from six consecutive patients with follicle centre lymphomas (FCLs) grade I or II (low-grade lymphomas), four patients with FCLs grade III and 11 patients with diffuse large B-cell lymphomas (DLBCLs) (high-grade lymphomas). We found gains of chromosome 7 in 14/18 successfully analysed cases (i.e. 2/6 FCLs grade I-II, 3/3 FLCs grade III and in 9/9 DLBCLs) using lymph node imprints. Moreover, the FISH technique demonstrated gains of chromosome 7 in 1/4 BM and 0/4 PB samples from FCLs grade I-II, in 2/4 BM and 2/4 PB specimens from FCLs grade III and in 4/9 BM and 2/9 PB samples from the DLBCLs. In contrast, morphologically recognizable lymphoma cells were seen in only 1/4 BM and 0/4 PB samples from the FCLs grade III and in 1/11 BM and 1/11 PB samples from the DLBCLs. We conclude that: (i) gain of chromosome 7 marks the progression from indolent to aggressive FCL and would appear to be a common finding in patients with FCLs grade III and in DLBCLs, (ii) clonal lymphoid cells occur frequently in BM and PB in high-grade lymphomas, making traditional staging by cytomorphology uncertain, and (iii) using gains of chromosome 7 as a marker of lymphoma cells, FISH is a useful method to detect minimal residual disease in FCLs grade III and DLBCLs.

show abstract

Lymphoma classification--the gap between biology and clinical management is closing

Cited by 65 publications

References 12 publications

The difference in NK‐cell activity between patients with non‐Hodgkin's lymphomas and Hodgkin's disease

The difference in NK‐cell activity between patients with non‐Hodgkin's lymphomas and Hodgkin's disease

2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma

Gain of chromosome 7 marks the progression from indolent to aggressive follicle centre lymphoma and is a common finding in patients with diffuse large B‐cell lymphoma: a study by FISH

Contact Info

Product

Resources

About